A new 2mg formulation of Narcan (naloxone hydrochloride; Adapt Pharma) Nasal Spray has been approved by the Food and Drug Administration (FDA), in addition to the 4mg strength already available. The spray is indicated for the emergency treatment of known or suspected opioid overdoses, as manifested by respiratory and/or central nervous system depression.
Narcan Nasal Spray is a ready-to-use, needle-free, concentrated version of naloxone that is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. It reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
Details around access and availability of the 2mg strength will be provided by Adapt upon its launch. Narcan Nasal Spray is available by prescription, however some states may allow the purchase of naloxone without the need for a prescription.
For more information visit Narcan.com.